Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (277)	6/2/1999 11:55:00 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 1475

Yeah, if you go through the thread, you'll see that I know RGEN well. I really like the trio that holds the place together, although the company almost went AWOL under the direction of former management. Don't understand the heavy emphasis on RGEN in the article, however, as the patent issued to BMY and RGEN is suing for co-inventor status. If you go back through the BGEN thread from about (?) 18 months ago, you'll see lots of our commentary on anti-CD40L and CTLA4-Ig. I was lucky to be one of the earliest to work with an anti-CD40L, as I did much of the quality control on Randy Noelle's (consults for and collaborates with Idec) anti-mouse antibody while at PharMingen. Good stuff! However, no reason to believe, from what I know, that anti-CD2 isn't just as good. However, as I've indicated, BGEN seems to be really rolling with anti-CD40L, while MEDI doesn't seen to be spreading 507 over many indications. This is right up my alley. Love this stuff.